Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kamari was established at the end of 2018 by the Israeli based biotechnology funds Pontifax and Arkin Bioholdings. Up to the current investment, $16 million were invested in Kamari. The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These drugs are intended for the treatment of various dermatological diseases, such as keratoderma, Lichen Simplex Chroni...
Kamari was established at the end of 2018 by the Israeli based biotechnology funds Pontifax and Arkin Bioholdings. Up to the current investment, $16 million were invested in Kamari. The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These drugs are intended for the treatment of various dermatological diseases, such as keratoderma, Lichen Simplex Chronicus and other severe genetic skin disorders.

List your booth number for exhibitions, ask us